Affiliation
Department of Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, USAIssue Date
2019
Metadata
Show full item recordAbstract
Limited stage small cell lung cancer (LS-SCLC) remains a challenging disease, with 5-year overall survival ranging from 30-35% with current standard of care treatment consisting of thoracic radiation to 45 Gy in 30 fractions delivered twice daily, with concurrent platinum/etoposide chemotherapy, followed by prophylactic cranial irradiation (PCI). The randomized, phase III CONVERT study confirmed 45 Gy delivered twice daily to be the optimal radiation fractionation regimen, without significantly increased toxicity when compared to daily radiation to 66 Gy. Immunotherapy is now being studied in addition to chemoradiation, in both the concurrent and consolidative setting. These randomized trials are ongoing. Additionally, the role of PCI compared to MRI surveillance is being evaluated in patients with LS-SCLC in both the North America and Europe. Ideally these ongoing studies will continue to improve outcomes for LS-SCLC.Citation
Higgins KA, Gorgens S, Sudmeier LJ, Faivre-Finn C. Recent developments in limited stage small cell lung cancer. Transl Lung Cancer Res. 2019;8(Suppl 2):S147-S52.Journal
Translational Lung Cancer ResearchDOI
10.21037/tlcr.2019.05.13PubMed ID
31673519Additional Links
https://dx.doi.org/10.21037/tlcr.2019.05.13Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.21037/tlcr.2019.05.13